KOD

Kodiak Sciences Inc

94.80

Sep 30 • 3:59 PM ET +3.68 (4.04%)

95.08

Aftermarket • 6:19 PM ET +0.28 (0.30%)

Healthcare Biotechnology USA Mid NASD

Sep 28, 10:20 PMKodiak's Phase 3 DAYBREAK wet AMD data show Zenkuda, tabirafusp-ted met endpoints with aflibercept-comparable efficacy, extended 6‑month dosing, favorable safety

Peers: KYMR CRNX INCY RYTM APGE KRYS VKTX BMRN AXSM NBIX

| Held by: XBI IWM VTI IBB IWO SCHA VXF FESM TMSL VTWO

Scroll to Statements

Index	RUT
Market Cap	5.96B
Enterprise Value	5.98B
Income	-241.99M
Sales	0.00M
Book/sh	0.97
Cash/sh	2.00
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	124
IPO	Oct 04, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	97.49
P/C	47.32
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	2.49
Current Ratio	2.49
Debt/Eq	2.50
LT Debt/Eq	2.34
Option/Short	Yes / Yes

EPS (ttm)	-4.19
EPS next Y	-3.85
EPS next Q	-1.06
EPS this Y	5.58%
EPS next Y	5.61%
EPS next 5Y	46.25%
EPS past 3/5Y	12.22% -8.23%
Sales past 3/5Y	- -
EPS Y/Y TTM	-10.60%
Sales Y/Y TTM	-
EPS Q/Q	-1.85%
Sales Q/Q	-
Earnings	Aug 13 AMC
EPS/Sales Surpr.	-9.78% -

Insider Own	7.46%
Insider Trans	67.04%
Inst Own	99.89%
Inst Trans	4.70%
ROA	-94.25%
ROE	-368.37%
ROIC	-118.60%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	123.73%
SMA50	128.70%
SMA200	171.63%
Trades

Shs Outstand	62.83M
Shs Float	58.16M
Short Float	18.35%
Short Ratio	7.77
Short Interest	10.67M
52W High	95.77 -1.01%
52W Low	10.94 766.54%
Volatility	20.73% 8.46%
ATR (14)	7.02
RSI (14)	90.54
Beta	2.08
Rel Volume	3.58
Avg Volume	1.37M
Volume	4,910,376

Perf Week	200.76%
Perf Month	153.82%
Perf Quarter	154.56%
Perf Half Y	148.69%
Perf YTD	239.06%
Perf Year	479.11%
Perf 3Y	5166.67%
Perf 5Y	-1.23%
Perf 10Y	-
Recom	1.33
Target Price	116.67
Prev Close	91.12
Price	94.80
Change %	4.04%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-24-26	Resumed	Goldman	Neutral	$36
May-11-26	Upgrade	Chardan Capital Markets	Neutral → Buy	$61
Nov-11-25	Upgrade	H.C. Wainwright	Neutral → Buy	$24
Oct-24-25	Upgrade	JP Morgan	Neutral → Overweight	$24
Sep-25-25	Upgrade	Barclays	Underweight → Equal Weight	$17
Sep-22-25	Initiated	Jefferies	Buy	$15
Aug-14-25	Upgrade	JP Morgan	Underweight → Neutral	$15
Dec-09-24	Upgrade	Jefferies	Hold → Buy	$20
Sep-05-24	Initiated	H.C. Wainwright	Neutral	$3
Dec-11-23	Resumed	Goldman	Sell	$2
Nov-17-23	Upgrade	CapitalOne	Equal Weight → Overweight	$7 → $12
Jul-27-23	Downgrade	UBS	Buy → Neutral	$15 → $4
Jul-25-23	Downgrade	JP Morgan	Neutral → Underweight
Jul-25-23	Downgrade	Chardan Capital Markets	Buy → Neutral
Jul-24-23	Downgrade	Jefferies	Buy → Hold
Jul-24-23	Downgrade	CapitalOne	Overweight → Equal Weight	$7
Nov-15-22	Initiated	CapitalOne	Overweight	$24
Aug-02-22	Downgrade	Citigroup	Neutral → Sell	$6
Feb-24-22	Downgrade	JP Morgan	Overweight → Neutral	$90 → $21
Feb-11-22	Initiated	Goldman	Buy	$70

Show Previous Ratings

Sep-29-26 05:24PM	This is the top biotech stock pick from B Riley Securities (Investing.com)
12:23AM	Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs? (Stocktwits)
12:01AM	New Eye Treatment Boosts Kodiak Into Ranks of Resurgent Biotechs (The Daily Upside)
Sep-28-26 10:13PM	KOD Stock Cracks Septembers Top 5 Biotech Gainers On Eye Drug Win But Pharma Bro Shkreli Says It Still Sucks (Stocktwits) +177.96%
04:14PM	Why This Regeneron Eye Rival Just Catapulted More Than 170% (Investor's Business Daily)
01:35PM	Loading…
01:35PM	Under the Radar: Kodiak Shares Surge as Eye Drug Matches Regeneron's (The Wall Street Journal)
01:04PM	Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial (Proactive)
12:11PM	Kodiak skyrockets on positive study data for 2 eye drugs (BioPharma Dive)
12:09PM	Kodiaks stock rallies on Phase III wAMD success (Clinical Trials Arena)
11:21AM	Kodiak Sciences Soars 141% on Truly Impressive Pivotal Wet AMD Trial Win (TIKR)
10:14AM	This Biotech Company Added Nearly $3B To Its Market Cap Heres Why KOD Stock Is Ripping Today (Stocktwits)
09:16AM	Kodiak Sciences stock soars on positive AMD trial data (Investing.com)
07:31AM	Kodiak Sciences Stock Pops 64% After Eye-Disease Drugs Pass Key Trial (Barrons.com)
07:02AM	Kodiak Sciences Shares Rise After DAYBREAK Phase 3 Trial Results (InvestorsHub)
06:30AM	Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Effect with Majority of Patients on 24-week Dosing Interval Using Strict Treat-to-Dryness Real World Retreatment Criteria. (PR Newswire)
06:01PM	Loading…
Sep-25-26 06:01PM	Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration (PR Newswire)
Aug-13-26 04:00PM	Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results (PR Newswire) -7.90%
Aug-10-26 04:43PM	Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema (PR Newswire)
Aug-06-26 07:00AM	Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026 (PR Newswire)
May-28-26 06:09PM	Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference (PR Newswire)
May-07-26 04:00PM	Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results (PR Newswire) -6.11%
May-01-26 12:23AM	Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences (PR Newswire)
Mar-31-26 04:45PM	Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results (PR Newswire) +13.25% +12.30%
Mar-27-26 08:23AM	How Kodiak Sciences Stock Rises To $120? (Trefis) -6.94%
Mar-26-26 06:46AM	Wave crashes on obesity drug update; Kodiaks reboot pays dividends (BioPharma Dive) +74.77%
06:00AM	Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda (tarcocimab tedromer) Over Sham (PR Newswire)
Feb-06-26 11:31AM	KOD Stock Up 24% in 3 Months: Here's What You Need to Know (Zacks) +9.66%
Feb-04-26 07:00AM	Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026 (PR Newswire) -6.87%
Jan-07-26 08:19PM	Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference (PR Newswire) +8.06%
Dec-30-25 08:45AM	The Biggest IPO of the Year Prompts Huge Insider Buy (24/7 Wall St.)
10:11AM	Loading…
Dec-22-25 10:11AM	What Awaits These 4 Biotech Stocks That More Than Doubled in 2025 (Zacks) +10.04%
Dec-18-25 08:26PM	Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Dec-16-25 10:55PM	Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock (PR Newswire) +11.77%
Dec-15-25 04:01PM	Kodiak Sciences Announces Proposed Public Offering of Common Stock (PR Newswire)
Nov-14-25 07:36AM	Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus (Zacks)
Nov-13-25 04:05PM	Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results (PR Newswire) -6.81%
Nov-12-25 05:48PM	Kodiak Sciences to Present at Upcoming Investor Conferences (PR Newswire)
Nov-05-25 07:00AM	Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (=90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI) (PR Newswire)
Sep-15-25 07:00AM	New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI) (PR Newswire)
Sep-12-25 11:30AM	Why Is Kodiak Sciences (KOD) Down 1.2% Since Last Earnings Report? (Zacks) -6.75%
Sep-02-25 08:00AM	Kodiak Sciences to Participate in Upcoming Scientific Conferences Highlighting KSI-101 in Patients with Macular Edema Secondary to Inflammation (MESI) (PR Newswire)
Aug-29-25 03:05PM	Jim Cramer on Kodiak Sciences: "That's a Pure Spec Stock" (Insider Monkey)
Aug-26-25 07:52PM	Lightning Round: Oklo goes up every time there's a good headline, buy Oklo, says Jim Cramer (CNBC TV)
Aug-19-25 02:18PM	Kodiak Sciences to Present at American Chemical Society Fall 2025 (PR Newswire) -15.73%
Aug-14-25 11:41AM	Kodiak Q2 Loss Wider Than Expected, Pipeline Development in Focus (Zacks) +16.47%
Aug-13-25 04:00PM	Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results (PR Newswire)
Jul-10-25 08:00AM	Kodiak Sciences to Host Investor R&D Day on July 16, 2025 (PR Newswire)
Jun-25-25 04:45PM	Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society (PR Newswire)
Jun-24-25 05:51AM	Age-Related Vision Dysfunction Market Research 2025-2035 \| Kodiak Sciences, Genentech, and AbbVie Drive Innovations Through Advanced, Sustainable Solutions (GlobeNewswire)
Jun-13-25 11:30AM	Why Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report? (Zacks) +5.43%
May-29-25 09:32PM	Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference (PR Newswire)
May-15-25 11:04AM	Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus (Zacks) -15.48%
May-14-25 04:15PM	Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results (PR Newswire)
May-01-25 11:43PM	Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases (PR Newswire) +6.90%
Apr-01-25 09:35AM	Down -28.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Kodiak Sciences (KOD) (Zacks) -8.73%
Mar-28-25 09:45AM	Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
Mar-27-25 04:01PM	Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Mar-26-25 03:58PM	Is Kodiak Sciences Inc. (KOD) The Hot Biotech Stock Under $5? (InsiderMonkey) -6.08%
Mar-10-25 04:39PM	Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy (PR Newswire)
Feb-04-25 07:30AM	Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025 (PR Newswire)
Jan-13-25 04:26PM	Heres Why Kodiak Sciences Inc. (KOD) Is Skyrocketing (Insider Monkey) -6.13%
Jan-07-25 06:00AM	Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-09-24 09:18PM	Nona Biosciences and Kodiak Sciences Partner on Next-Generation Antibody Therapies for Ophthalmic Diseases (PR Newswire) +29.63%
12:33PM	Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock (Benzinga)
Nov-25-24 09:55AM	Kodiak Sciences Inc. (KOD) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
Nov-14-24 04:01PM	Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results (PR Newswire)
Nov-11-24 06:15AM	Kodiak Sciences to Participate in Upcoming Investor Conferences (PR Newswire) +8.54%
Oct-14-24 05:35PM	Kodiak Sciences to Present at Innovate Retina 2024 (PR Newswire)
Sep-23-24 06:00AM	Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time (PR Newswire)
Sep-17-24 04:05PM	Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City (PR Newswire)
Sep-13-24 11:30AM	Why Is Kodiak Sciences (KOD) Down 8.1% Since Last Earnings Report? (Zacks) +13.87%
Aug-16-24 10:42AM	Kodiak (KOD) Q2 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
Aug-14-24 09:54PM	KOD Stock Earnings: Kodiak Sciences Beats EPS for Q2 2024 (InvestorPlace)
04:01PM	Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results (PR Newswire)
Jul-10-24 12:00PM	All You Need to Know About Kodiak Sciences (KOD) Rating Upgrade to Buy (Zacks)
Jun-20-24 08:23AM	Should You Hold Kodiak Sciences (KOD) Stock in Your Portfolio? (Zacks)
Jun-14-24 11:30AM	Why Is Kodiak Sciences (KOD) Down 26.2% Since Last Earnings Report? (Zacks)
May-29-24 04:36PM	Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences (PR Newswire)
May-16-24 12:51PM	Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
May-15-24 10:55PM	KOD Stock Earnings: Kodiak Sciences Beats EPS for Q1 2024 (InvestorPlace)
04:01PM	Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results (PR Newswire)
May-14-24 07:31AM	Kodiak Sciences dosing subjects in Phase III trial of diabetic retinopathy drug (Clinical Trials Arena)
May-13-24 07:32PM	Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy (PR Newswire) +6.09%
May-02-24 04:30PM	Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform (PR Newswire)
Apr-04-24 12:09PM	Kodiak (KOD) Counts on Tarcocimab Program Despite Setbacks (Zacks)
Apr-01-24 05:04PM	Kodiak Sciences Inc. (NASDAQ:KOD) Q4 2023 Earnings Call Transcript (Insider Monkey) -15.40%
12:00PM	Kodiak (KOD) Stock Falls on Q4 Earnings Miss, Pipeline in Focus (Zacks)
Mar-29-24 10:36AM	Q4 2023 Kodiak Sciences Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-28-24 11:53AM	KOD Stock Earnings: Kodiak Sciences Misses EPS for Q4 2023 (InvestorPlace) -29.40%
08:32AM	Kodiak Sciences Inc (KOD) Posts Q4 and Full Year 2023 Financial Results (GuruFocus.com)
06:30AM	Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
Mar-26-24 06:15AM	Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024 (PR Newswire) +16.01%
Jan-30-24 06:30AM	Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting (PR Newswire) -8.58%
Jan-04-24 04:15PM	Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-14-23 11:30AM	Kodiak Sciences Inc. (KOD) Up 43.6% Since Last Earnings Report: Can It Continue? (Zacks) +6.21%
Nov-21-23 04:15PM	Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference (PR Newswire) -7.41% +6.67%
Nov-15-23 08:00AM	Kodiak (KOD) Beats Q3 Earnings, Provides Pipeline Updates (Zacks) +5.21%
Nov-14-23 06:09PM	Kodiak Sciences Inc (KOD) Reports Q3 2023 Financial Results: Net Loss Narrows, R&D Expenses ... (GuruFocus.com) +6.67%
04:01PM	Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights (PR Newswire)
Nov-06-23 05:00AM	Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission (PR Newswire) -13.56%

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Co-FounderDr. Victor Perlroth M.D.

M.B.A.Mr. John A. Borgeson CPA

Chief Technology OfficerMr. Wayne To M.Phil.

M.P.H.Dr. Dolly S. Chang M.D.

Senior Vice President of DevelopmentDr. Hong Liang Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BAKER BROS. ADVISORS LP	Director	Sep 28 '26	Buy	88.77	681,866	60,529,354	20,159,386	Sep 30 04:31 PM
BAKER BROS. ADVISORS LP	Director	Sep 29 '26	Buy	85.05	33,726	2,868,255	20,191,214	Sep 30 04:31 PM
BAKER BROS. ADVISORS LP	Director	Sep 28 '26	Buy	83.58	418,323	34,963,077	19,515,907	Sep 30 04:30 PM
BAKER BROS. ADVISORS LP	Director	Sep 28 '26	Buy	72.57	807,840	58,625,708	19,121,134	Sep 30 04:29 PM
PERLROTH VICTOR	Chairman and CEO	Sep 25 '26	Option Exercise	4.20	1,280,524	5,381,943	3,676,062	Sep 29 07:44 PM
BORGESON JOHN A.	Chief Financial Officer	Jun 04 '26	Option Exercise	1.04	30,000	31,200	241,930	Jun 05 05:56 PM
BORGESON JOHN A.	Chief Financial Officer	Jun 04 '26	Sale	34.10	30,000	1,023,009	211,930	Jun 05 05:56 PM
JOHN BORGESON	Officer	Jun 04 '26	Proposed Sale	33.87	30,000	1,016,100		Jun 04 04:29 PM
BORGESON JOHN A.	Chief Financial Officer	Apr 15 '26	Option Exercise	1.04	28,614	29,759	211,930	Apr 16 05:00 PM
BORGESON JOHN A.	Chief Financial Officer	Apr 02 '26	Option Exercise	1.04	30,000	31,200	213,316	Apr 02 08:26 PM
BORGESON JOHN A.	Chief Financial Officer	Apr 02 '26	Sale	39.92	30,000	1,197,488	183,316	Apr 02 08:26 PM
JOHN BORGESON	Officer	Apr 02 '26	Proposed Sale	42.81	30,000	1,284,300		Apr 02 04:23 PM
PERLROTH VICTOR	Chairman and CEO	Mar 25 '26	Option Exercise	1.04	300,000	312,000	2,395,538	Mar 27 06:08 PM
BAKER BROS. ADVISORS LP	Director	Dec 18 '25	Buy	23.00	2,608,696	60,000,008	18,358,772	Dec 19 04:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KOD

Kodiak Sciences Inc

Upgrade your Finviz experience